Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-03

FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)

View source ↗

Summary

The FDA approved a supplemental application for buprenorphine hydrochloride submitted by PAI Holdings/PAI Pharma, authorizing changes to the approved generic pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine Hydrochloride (Buprenorphine hydrochloride)

Snippet

SUPPL AP for BUPRENORPHINE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE)